Index

a
Activation tagging mutagenesis (ATM) 437–439, 442, 444–447, 451
Acyl sugars 360
Adjuvant 256
Agrobacterium rhizogenes 442, 444, 445, 447
Agroinfiltration 236
Albumin 106
Alcoholism 439
Alkaloids 400
Allergy 260
Antibodies 7, 107
Antibody isoforms 220
Aptamer 203, 204
Arabidopsis thaliana 438
Artemisia annua 356
Artemisinin 358
Avidin 345

b
Biobetter 340
Biodistribution 200, 202, 203, 206, 207
Bioencapsulation 15
Biosimilar 340
Blood–brain barrier (BBB) 202–205
B lymphocyte 233
Bridge vector 239

c
Callus, calli 437, 438
Canine parvovirus 254
Capillary electrophoresis 419
Catharanthus roseus 438, 448
Central nervous system (CNS) 435, 440
Cerezyme 340
Chimeric plant virus 252
Chimeric virus–like particle (VLP) 249
Chinese hamster ovary cell cultures 183–186, 188, 199, 205
Cholera toxin (CTB) 258
Clarification methods 15
Clinical trial 242
Clinical Trials Directive 344
Clostridium perfringens 260
Clustered regularly interspaced short palindromic repeats (CRISPR) 29
Compassionate use program 342
Complement C1q 257
Complex glycan deficient (cgl) mutant 187, 188, 191, 192, 198, 199
CRISPR-associated (Cas9) 347
Cryopreservation 341
CTS region 74
Curcuminoids 400
Current good manufacturing practice (cGMP) 332, 337
Cytochrome P450 oxygenase 361
Cytotoxic T lymphocytes (CTL) 233
d
D-amino acid oxidase 452, 453
Databases 57
Deconstructed viral vector 238
Defense Advanced Research Projects Agency (DARPA) Blue Angel program 246
Dengue virus 257
Dihydroxytryptamines 439
D-isoleucine 452, 453
Diterpenes 392
Downstream processing
  challenges, proteases 146
  recovery phase 145
Drug dependence 440
Drug discovery 430
Duckweed (Lemna minor) 335, 340
Endoplasmic reticulum 70
Endoplasmic reticulum associated degradation (ERAD) 188
Enzyme replacement therapy (ERT)
  182–187, 189, 192, 193, 194ff, 198, 200–207
Epidermal growth factor receptor (EGFR) 417
Escherichia coli heat-labile enterotoxin 258
Estrogen receptor (ER) 438, 452
Estrogen receptor (ERα) 452, 453
Estrogen receptor (ERβ) 452, 453
Ethanol-inducible promoter 239
Flavonoids 360, 398
Fluorescent substrate, peptide 421
Foot-and-mouth disease virus (FMDV) 250
Fucosyltransferase 72
Galactosyltransferase 74
GalNAc-transferase (GalNAc-T) 80
Gas chromatography-mass spectrometry (GC/MS) 437, 443, 446, 450, 451
Gaucher disease 181–186, 192, 340
Geminiviral vector 257
Genetically modified (GM) crops, regulation 331
Genetically modified organism (GMO) 330, 347, 454
Genome conservation 461
Genome editing 81
Glandular trichomes 355
Glucocerebrosidase (Elelyso) 10, 182–188, 191, 192, 340
Glucocorticoid receptor 438
Glucosinolates 402
Glucuronidase (β-Glucuronidase) 345
Glycan microarrays 56
Glycosidases 55
Glycosyltransferase 72
Golgi complex 67
Golgi α-mannosidase I (GMI) double mutant 189, 192
Gut-associated lymphoid tissue (GALT) 232
Hairy root 438–440, 442–448
Hemagglutinin 343
Hematopoietic stem cell transplantation (HSCT) 202
Hepatitis B surface antigen (HBsAg) 245
Hepatitis B virus (HBV) 244
Hexosaminidase 71
High throughput screening 418
High-mannose N-glycans 188, 190ff
HIV, AIDS 247
H1N1 343
H5N1 343
HPLC-MS/MS 419
Human dopamine transporter (hDAT) 440–446, 449
Human nuclear receptors 438
Human papillomavirus (HPV) 242
IC50 425
Iduronidase (α-l-iduronidase) 182–192, 198–200
IgA O-glycans 225
IgG-Fc glycosylation 221
IgM, IgA; N-glycosylation of 224
Immune complex 256
Immunoglobulin A (IgA) 79, 241
Immunoglobulin G (IgG) 232, 241
Inducible expression 342
Influenza vaccine 343
Influenza virus 246
Inhibitor 417
Insulin 106

**k**
Kinases 462
assay 418

**l**
Lectins 56
LEX system 340
Lipase 314
Living modified organism (LMO) 330, 347
Locteron 11, 340
Lysosomal storage diseases (LSDs) 182–185, 187, 196, 202, 207, 316
Lysosomal targeting 193, 194ff, 195
Lysozyme 345

**m**
Mannose receptor 192, 202
Mannose-6-phosphate
  in planta 200, 201ff
  receptors 185, 193, 194, 197–199, 202, 207
tag 182, 192, 193, 194ff, 195, 198–200, 202, 206
in vitro 195, 198–200
Mannosidases 45, 70
Master cell bank 333
Master seed bank 333
Membrane anchor 101
*Mentha x piperita* (peppermint) 356
Methylketone 359
Metabolic engineering 366
Metabolic pathways 36
Microprojectile bombardment 234
Mn peroxidase 311
Modeling 33
Molecular farming
  overview 329
  platforms 330, 334
  regulation 330, 336, 338–339, 346
Molecular pharming, evolution of 137
Molecular Trojan horse 203–205
Monoterpenes 388
Mucopolysaccharidosis I (MPS I) 182–186, 202–204, 206
Mucosal delivery 16
Mucosal immunity 241
Multi-histocompatibility complex (MHC) 233

**n**
N-acetylglicosaminyltransferases 46, 70, 191
Natural products 418
Neurodegenerative diseases 458
Newcastle disease virus (NDV) 341
*N*-Glycans 44, 68
  analysis methods (HPLC, UPLC, MS, CE) 49ff
  analysis methods (MALDI, ESI) 53ff
  engineering 71, 222
  maturation 189, 190ff
  modification 109
  processing 69
  trimming 189, 190ff, 192
*N*-Glycosylation 68, 188, 189, 190ff
*Nicotiana benthamiana* 237, 317, 342, 366
*Nicotiana tabacum* (tobacco) 356
Nicotinic acetylcholine receptors 440
Norovirus 240
Nuclear integration 234

**o**
OFF switch 33
O-glycans 44
  engineering 77
  processing 78
O-glycosylation 77
Oil bodies 103, 124
ON switch 31
Oral immunization 241
Oral tolerance 260
Oral vaccines 139
Orphan Drug Act 318, 340
Oscillator 33
Oxidative stress 466

**p**
Peptide:N-glycosidase (PNGase)/endoglycosidase 47
Polychlorinated biphenyl (PCB) 311
Percentage of inhibition 424
Peroxidase 311–313, 315
Persistent organic pollutants (POPs) 311, 312
Pharma-Planta 344
Phase II clinical study 247
Phenolics and pigments 162
Phospholipase 315
Phosphotransferase (UDP-GlcNAc-1-phosphotransferase) 190, 194, 195, 198–200, 201ff
Phytase 313
Phytate 313
Phytic acid (salts) 156
Plant cell suspension cultures 334
Plant-made pharmaceuticals (PMPs) 320, 331, 347
Plant organelles, seed 95
Plastid genome 235
Polysaccharides 160
Post-transcriptional gene silencing, suppressors of 121
ProCellEx 340
Prodigene Inc. 345
Production capacity 13
Prolyl 4-hydroxylases 77
Promoters 34, 120
Proteases 463
Protein aggregation 100
Protein bodies 125
Protein derived from host 151
Protein misfolding 464
Protein storage organelles 124
vacuoles 97, 125
Purification tags 140

q
Quercetin 428

r
Rabies virus 253
Rare diseases 316
Recombinant HSA (OsrHSA) characterization of 279
downstream processing 278
efficacy of 301
pharmacokinetic features of 301
production challenges and strategies 275
safety assessment of 295
Recombinant protein production
general plant platforms 141
using bioreactor-based systems 144
using leaf-based systems 142
using seed-based systems 143
Recombinant protein products; trends, niche markets 139
Renewable fuel standard (RFS) 313
Reporters 35
Rice suspension cells 342
Ricin toxin subunit B (RTB) 319
RNA interference (RNAi) 235
Rutin 428

s
Salvage pathway 185, 193
Secretory pathway 98
Sesquiterpenes 388
Solanum lycopersicum (tomato) 356
Sialylation 76
Small Business Innovation Research (SBIR) 310
Stilbenoids 399
Storage compartment 108
Subcellular targeting 123
Successful plant-recombinant proteins, Elelyso™, ZMapp™ 138
Sulfamidase 317
Sulfatase-modifying factor 1 318
Systematic evolution of ligands by exponential enrichment (SELEX) 204

t
Taliglucerase alfa 340
Targeting route 98
Terpene synthase 358
Terpenoids 358
Tetanus toxin 257
Tetraterpenes 394
Thermotolerance 463
T lymphocyte 233
Tobacco mosaic virus (TMV) 344
Tobacco suspension cells 341
Traditional Chinese medicine 418
Transcription factors 369
Transgenic plants 335
strawberries 344
tobacco 344
Transient expression 6, 236, 317, 335
Transient response 33
Transplastomic plant 259
Triterpenes 391
Trypzean™ 311
Tumor necrosis factor; tumor necrosis factor receptor 184, 203–205
Tyrosine sulfation 223

U
Ubiquitin ligase 462
Uncovering enzyme 190, 193, 194ff, 197–200, 201ff
US Food and Drug Administration 181, 182, 203, 204

V
Vaccines 9, 107
Vacuum infiltration 319
Vesicular pathway, dense vesicle, precursor accumulating 99
Viral vector 237
Virus-like particles 9, 239

W
Whole or minimally processed plants 140
Working cell bank 333
Working seed bank 333

X
Xylosyltransferase 72

Z
ZMapp™ 11, 342